Nab-paclitaxel plus capecitabine as a first-line regimen for advanced biliary tract cancers: Feasible or not feasible?

doi:10.3748/wjg.v31.i10.100771

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 31, Issue 10

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (0)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-2) series.

Item

Count

PDF

HTML

Figures (1-1)

Tables (1-2)

Sum=0

Mar 14, 2025 (publication date) through Feb 26, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Letter to the Editor

World J Gastroenterol. Mar 14, 2025; 31(10): 100771
Published online Mar 14, 2025. doi: 10.3748/wjg.v31.i10.100771

Open in New Tab Full Size Figure Download Figure

Figure 1 History of systemic therapy for advanced biliary tract cancers. 5-FU: 5-fluorouracil combination chemotherapy; G: Gemcitabine; C: Cisplatin; D: Durvalumab P: Pembrolizumab.

Citation: Chen JQ, Lan X. Nab-paclitaxel plus capecitabine as a first-line regimen for advanced biliary tract cancers: Feasible or not feasible? World J Gastroenterol 2025; 31(10): 100771
URL: https://www.wjgnet.com/1007-9327/full/v31/i10/100771.htm
DOI: https://dx.doi.org/10.3748/wjg.v31.i10.100771